Cowen and Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Cowen and Company’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,000	Closed	-$11K	–	652
2022 Q1	$11K	Buy	+9,000	New	+$218K	﹤0.01%	491
2021 Q2	–	Sell	-7,500	Closed	-$148K	–	586
2021 Q1	$148K	Buy	+7,500	New	+$330K	0.01%	293
2020 Q4	–	Sell	-20,800	Closed	-$51K	–	397
2020 Q3	$51K	Buy	+20,800	New	+$898K	0.01%	298

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cowen and Company's ACAD Position: Q4 2021 in Review

Cowen and Company sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 5,121 shares — an estimated $85K sold.

Cowen and Company first reported a position in ACAD in Q3 2020 and held it in 3 quarters. The position peaked at $194K in Q1 2021. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

Cowen and Company reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Cowen and Company sold 5,121 Acadia Pharmaceuticals shares in Q4 2021, an estimated $85K.
Cowen and Company first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 3 quarters.
Cowen and Company's Acadia Pharmaceuticals position peaked at $194K in Q1 2021.
247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.